Related Experiment Video

Updated: May 26, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Pazopanib for the treatment of breast cancer

Laleh Amiri-Kordestani1, Antoinette R Tan, Sandra M Swain

  • 1National Cancer Institute, 10 Center Drive, 12N226, Bethesda, MD, USA.

Expert Opinion on Investigational Drugs
|January 12, 2012
PubMed
Abstract

Insights

Pazopanib, an angiogenesis inhibitor, shows anti-tumor activity in preclinical models and is being evaluated in breast cancer trials. Biomarker development is crucial for guiding treatment decisions with these agents.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Angiogenesis inhibitors offer clinical benefits for solid tumors.
  • Pazopanib, a tyrosine kinase inhibitor, is approved for advanced renal cell carcinoma (RCC).

Purpose of the Study:

  • To review the clinical development of pazopanib for breast cancer.
  • To examine pazopanib's efficacy, safety, and preclinical data in breast cancer.

Main Methods:

  • Review of preclinical data demonstrating pazopanib's anti-tumor effects.
  • Evaluation of completed and ongoing clinical trials of pazopanib in breast cancer (monotherapy and combination).

Main Results:

  • Preclinical studies support pazopanib's anti-tumor activity.
  • Clinical trials are assessing pazopanib's role in breast cancer treatment.

Conclusions:

  • Predictive biomarkers for response and toxicity to angiogenesis inhibitors are essential.
  • Biomarker development is critical for personalized treatment strategies in breast cancer.

More Related Videos

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...